[Selection of blood products to reduce immunization before HLA-mismatched allogeneic transplantation (SFGM-TC)]

The increase of HLA-mismatched allogeneic stem cell transplantation, due to the use of post-transplant high-dose cyclophosphamide, has highlighted the detrimental impact of anti-HLA antibodies in the recipient, especially those directed against the donor (donor specific antibodies [DSA]), on transplant success. Blood products transfusions, in particular platelets, are a source of immunisation against donor HLA antigens and patients candidates to HLA-mismatched transplantation are at risk of developing DSA because of the elevated transfusion need. This Atelier gathers Immunogenetics and Transfusion Medicine experts to deal with the prevention of anti-HLA immunisation of patients waiting to HLA-mismatched transplantation, through the appropriate selection of blood products thus avoiding the appearance of DSA and optimising the engraftment rate.